Search research articles
Contact Us
Filters
Showing results (71-80 of 79) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 79 results.
Leukemia & Lymphoma
|
May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Shaji Kumar, Brian Durie, Hareth Nahi, et al.
Advances in Therapy
|
January 6, 2025
Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023
Ataru Igarashi, Shiro Tanaka, Raf De Moor, et al.
Advances in Therapy
|
November 12, 2024
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023
Ataru Igarashi, Shiro Tanaka, Raf De Moor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 6, 2024
A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices
Shiro Tanaka, Ataru Igarashi, Raf De Moor, et al.
Current Medical Research and Opinion
|
July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Annals of Internal Medicine
|
June 2, 2015
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
Brian Hutton, Georgia Salanti, Deborah M Caldwell, et al.
Leukemia & Lymphoma
|
January 6, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Karen W L Yee, et al.
Cancer Medicine
|
August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
Stéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Leukemia & Lymphoma
|
September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 79) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 79 results.
Leukemia & Lymphoma
|
May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Shaji Kumar, Brian Durie, Hareth Nahi, et al.
Advances in Therapy
|
January 6, 2025
Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023
Ataru Igarashi, Shiro Tanaka, Raf De Moor, et al.
Advances in Therapy
|
November 12, 2024
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023
Ataru Igarashi, Shiro Tanaka, Raf De Moor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 6, 2024
A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices
Shiro Tanaka, Ataru Igarashi, Raf De Moor, et al.
Current Medical Research and Opinion
|
July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Annals of Internal Medicine
|
June 2, 2015
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
Brian Hutton, Georgia Salanti, Deborah M Caldwell, et al.
Leukemia & Lymphoma
|
January 6, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Karen W L Yee, et al.
Cancer Medicine
|
August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
Stéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Leukemia & Lymphoma
|
September 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, et al.
Page
of 8